December 2013 Supplement - Endovascular Today

Table of Contents

Supplement

December 2013 Supplement

Innovating For Clinical Performance

Valiant® Mona LSA Stent Graft Selected by the FDA for an early feasibility pilot program

In This Supplement

Download PDF

From Benchtop to Bedside With the Valiant Mona LSA Thoracic Stent Graft

How physicians, engineers, and regulatory agencies can work together to best serve patients with new technologies.

By Frank R. Arko, III, MD

Branch Technology: Innovation in the Development Process

Increasing AAA and TAA patient applicability while ensuring quality from design to market.

By Peter Larson, MS, BS; Emilie Simmons, MS; and Paige Bota, BS, PhD

Why Evidence Matters in Innovation

The importance of clinical evidence in today's medical practice.

By Kenneth Ouriel, MD, MBA

Empowering EVAR Clinical Performance

Endurant II Stent Graft Durable Outcomes in the ENGAGE Real-World Registry

By Pieter P.H.L. Broos, MD; Philippe W.M. Cuypers, MD, PhD; Joep A.W. Teijink, MD, PhD; and Marc R.H.M. van Sambeek, MD, PhD

Consistent Durable Outcomes At 3-Year Follow-Up Across Endurant Trials*

Empowering EVAR clinical performance.

By Sharif H. Ellozy, MD

Addressing Challenging AAA Anatomies With Confidence

Hence J.M. Verhagen, MD, PhD, discusses how the Endurant II Stent Graft has performed well in challenging anatomy, enabling physicians to successfully treat a broader range of AAA patients.

Latest Issues

March 2026

February 2026

January 2026

December 2025

November 2025

View All Issues

In This Supplement

Most Read Articles